Management of Hepatocellular Carcinoma: Future Directions in Care
Expert insight to how the field of hepatocellular carcinoma management may evolve in coming years given therapeutic combinations and ongoing clinical trials.
Patient Profile 3: Advanced HCC Treated With Cabozantinib in Second Line
Centering discussion on the final patient profile, panelists consider how they select optimal therapy in the second-line setting of advanced hepatocellular carcinoma.
Treatment Options for Advanced HCC in the Second-Line and Beyond
Brief but comprehensive insight to the cornerstone second-line treatment options in the setting of recurrent advanced hepatocellular carcinoma.
Novel First-Line Immunotherapy Approaches in Advanced HCC
Panelists close out their discussion on first-line treatment options for advanced HCC with a review of single-agent and combination immunotherapy approaches.
Real-World Use of Durvalumab + Tremelimumab in Advanced HCC
In the context of clinical data from the HIMALAYA and STRIDE trials, expert oncologists review real-world use of tremelimumab + durvalumab in advanced HCC.
Patient Profile 2: A 70-Year-Old Man With Advanced HCC Treated With Durvalumab + Tremelimumab
Focusing on a second patient profile of advanced hepatocellular carcinoma, panelists consider the role of first-line tremelimumab + durvalumab.
Real-World Use of First-Line Lenvatinib Therapy in Advanced HCC
Comprehensive discussion on the real-world applications of first-line lenvatinib therapy in advanced HCC followed by its potential in combination with TACE.
Advanced HCC: Clinical Trial Data Behind First-Line Therapy Options
Expert oncologists take a look at clinical trial data as they pertain to prevalent first-line systemic therapy options in advanced hepatocellular carcinoma.
Selecting the Appropriate First-Line Therapy for Advanced HCC
In the context of the first patient profile, expert panelists consider which factors play into their selection of first-line systemic agents in advanced hepatocellular carcinoma.
Patient Profile 1: A 77-Year-Old Man with Advanced HCC Treated With Lenvatinib
Focusing on the first patient profile of advanced hepatocellular carcinoma, Andrea Casadei-Gardini, MD, reviews his selection and use of first-line lenvatinib therapy.
Advanced HCC: Updates in First-line Systemic Therapy
Moderator Josep Llovet, MD, centers discussion on advanced hepatocellular carcinoma and provides a broad overview of treatment options in the frontline setting.
Role of Systemic Therapy in Early- or Intermediate-Stage HCC
Expert perspectives on the selection and use of systemic therapy in patients who progress on or are unsuitable for locoregional therapies.
Role of Locoregional Therapy in Early- or Intermediate-Stage HCC
Comprehensive insight on the role of locoregional therapies in early- or intermediate-stage HCC, alone or in combination with systemic agents.
Early- and Intermediate-Stage HCC Treatment Landscape
Opening their discussion on the management of hepatocellular carcinoma, expert panelists take a broad look at the treatment landscape.
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Both Gastric and Breast HER2 Scoring Algorithms Applicable in mCRC Testing
Encorafenib Plus Cetuximab and Chemotherapy Demonstrates Safety, Efficacy in BRAF V600E–Mutant mCRC
2 Clarke Drive Cranbury, NJ 08512